Print Page   |   Sign In   |   Register
Companies: Cellectar Biosciences, Inc. (CLRB)

Company Profile

Description

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar's compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. A Phase II trial evaluating I-124-CLR1404 in glioblastoma is expected to be completed in 2014. Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com  

 

Contact Information

  • 3301 Agriculture Drive
  • Madison, WI 53716

Financial Reporting/Disclosure

Reporting Status U.S. Reporting: SEC Reporting
Latest Report Jun 30, 2016 10-Q
CIK 0001279704
Fiscal Year End 12/31
OTC Marketplace Not Available

Profile Data

SIC - Industry Classification Not Available
Business Status Development Stage Company a/o Feb 13, 2014
Incorporated In: DE, USA
Year of Inc. 1996
Employees 17 a/o Jan 01, 2012

Company Notes

  • Formerly=Novelos Therapeutics, Inc. until 2-2014
  • Formerly=Common Horizons, Inc. until 6-05

Service Providers

Accounting/Auditing Firm
Grant Thornton 
200 South Orange Avenue
Suite 2050
Orlando, FL, 32801
United States

Legal Counsel
Foley Hoag LLP
World Trade Center West
155 Seaport Boulevard
17th Floor
Boston, MA, 02210
United States

Investor Relations Firm
Lippert/Heilshorn & Associates
800 Third Avenue
17th Floor
New York, NY, 10022
United States

 

 
Community Search
Sign In